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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe generation of tissue-specific cell types from human embryonic stem cells (hESCs) is critical for the development of future stem cell-
based regenerative therapies. Here, we identify CD13 and ROR2 as cell-surface markers capable of selecting early cardiac mesoderm
emerging during hESC differentiation. We demonstrate that the CD13+/ROR2+ population encompasses pre-cardiac mesoderm, which
efficiently differentiates to all major cardiovascular lineages. We determined the engraftment potential of CD13+/ROR2+ in small
(murine) and large (porcine) animalmodels, and demonstrated that CD13+/ROR2+ progenitors have the capacity to differentiate toward
cardiomyocytes, fibroblasts, smooth muscle, and endothelial cells in vivo. Collectively, our data show that CD13 and ROR2 identify a
cardiac lineage precursor pool that is capable of successful engraftment into the porcine heart. These markers represent valuable tools
for further dissection of early human cardiac differentiation, and will enable a detailed assessment of human pluripotent stem cell-
derived cardiac lineage cells for potential clinical applications.INTRODUCTION
The mammalian heart has been reported to possess a
limited regenerative capacity; however, this is not suffi-
cient to effectively remuscularize the heart after a myocar-
dial infarction (MI) (Ali et al., 2014). In the case of severeMI
the human heart experiences dramatic loss of cardiomyo-
cytes, the basic functional unit of the heart, with estimates
placing that loss upward of a billion cells (Bergmann et al.,
2009; Laflamme and Murry, 2005). As heart disease con-
tinues to be a leading cause of mortality worldwide, the
use of human pluripotent stem cells (hPSCs) for cardiac
regeneration is a compelling approach and has become a
major focus of stem cell research (Cibelli et al., 2013; Matsa
et al., 2014). Indeed, the first human subject receiving
hPSC-derived cardiovascular progenitors as a therapeutic
for heart failure has recently been reported (Menasche
et al., 2015).
The progression of in vitro-derived cardiac cells toward
therapeutic applications will be greatly assisted by an
increasingly detailed understanding of cardiac lineage
commitment. Moreover, it is still unclear whether
committed progenitors or fully differentiated cells will be
most efficacious for any particular therapeutic use. Indeed,
homogeneous populations of cardiovascular progenitorStemcells that have the capacity to form multiple cardiac cell
types (e.g., cardiomyocytes, fibroblasts, and vascular cells)
may have a role to play in future stem cell-based therapies.
In this context, further research is required to elaborate the
cardiac lineage tree and to devise methods for isolating key
cell types and their progenitors.
Generation of a pure hPSC-derived cardiac population
through an intermediate mesodermal germ layer (from
which the cardiac tissue arises) may be of therapeutic
importance. Previous studies have identified SSEA1,
PDGFRa, and KDR as surfacemarkers on PSC-derivedmeso-
dermal progenitors with capacity to generate cardiovascu-
lar lineages (Blin et al., 2010; Kattman et al., 2011; Yang
et al., 2008). Subsequently, SIRPA and VCAM1 were identi-
fied as novel markers of cardiomyogenic lineages (Dubois
et al., 2011; Elliott et al., 2011; Skelton et al., 2014; Uosaki
et al., 2011). These studies provide a foundation upon
which to construct a human cardiovascular cell lineage
tree based on cell-surface markers, analogous to that of
the hematopoietic system.
Other surface markers, such as CD13 and ROR2, have
been used in combinationwith PDGFRa and KDR to isolate
progenitors capable of giving rise to enriched cardiac
cell populations (Ardehali et al., 2013). The combination
of these four markers led to isolation of committedCell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authors 95
cardiovascular cells as shown by in vitro and in vivo ana-
lyses. However, the utility of CD13 and ROR2 as stand-
alone markers of cardiac intermediates remains unclear.
Here, we define CD13 and ROR2 as markers of mesodermal
progenitors of cardiac cell lineages. Furthermore, in vivo
cardiac differentiation and engraftment efficiency of
CD13+/ROR2+ cells was compared in large (porcine) and
small (murine) animal models. Our data demonstrate that
human embryonic stem cell-derived cardiovascular pro-
genitor cells (hESC-CPCs) engraft and differentiate into all
cardiovascular lineagesmore efficiently in theporcineheart
than in the mouse heart. Consistent with previous reports,
these data suggest that themurineheartmaybe an inappro-
priate xenotransplantation model (Cibelli et al., 2013; van
Laake et al., 2008, 2009). The pig heart, however, may pro-
vide a useful pre-clinical platform upon which to test the
regenerative potential of hESC-CPCs (Ye et al., 2014).
Collectively, these findings enhance our understanding of
cardiac mesoderm lineage formation, provide well-defined
tools for the enrichment of cardiac-committed mesoderm,
and demonstrate engraftment and differentiation of trans-
planted hESC-CPCs in porcine hearts.RESULTS
CD13 and ROR2 Markers Can Be Used for Prospective
Isolation of Pre-cardiac Mesoderm Cells
Initially, a stencil differentiation protocol (Myers et al.,
2013) was used to isolate mesodermal cells based on GFP
expression from the MIXL1 locus (Davis et al., 2008) (Fig-
ure S1). Microarray analysis of isolated cells from day 3 of
differentiation was used to identify differences between
MIXL1eGFP+ andMIXL1eGFP transcriptomes.We identified
6,757 differentially regulated genes, of which 2,520 were
upregulated R2-fold in the eGFP+ (MIXL1+) mesoderm
population (Figure 1A). These included known meso-
dermal markers, such as T, PDGFRa, MESP1, and EOMES,
as well as two genes encoding for cell-surface proteins,
CD13 (an aminopeptidase) and ROR2 (aWnt receptor) (Fig-
ure 1A). To further investigate the expression profile of
CD13 and ROR2, we differentiated MIXL1eGFP/w hESCs to-
ward mesoderm and conducted flow cytometry analysis.
On day 3 of differentiation, approximately 30% of cells
co-expressed CD13 and ROR2 in several hPSC lines that
were tested (Figure 1B). More efficient differentiation
schemes using the H3 hESC line produced populations
consisting upward of 80% CD13+/ROR2+ cells (Figures
1C, S2A, and S2B). Later in differentiation, the majority
of cells downregulated CD13 while maintaining ROR2+
expression out to day 10 (92%) (Figure 1C). Flow cytom-
etry analysis also showed that approximately 70% of the
eGFP+ (MIXL1+) population expressed CD13 and ROR296 Stem Cell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authoon day 3 of differentiation (Figure 1D). Comparatively,
very few CD13+/ROR2+ (13R2+) cells were detected in
the eGFP (MIXL1) fraction (4%) (Figure 1D), suggest-
ing that CD13 and ROR2 are predominantly restricted to
a mesoderm population marked by MIXL1 expression. In
addition, qPCR analysis of 13R2+ cells confirmed the
high expression levels of cardiac precursor markers such
as PDGFRa (1.1 3 104-fold), HAND1 (5.4 3 103-fold),
MESP1 (530-fold), and EOMES (1.4 3 104-fold) relative to
GAPDH (Figure 1E). Subsequently, we performed expres-
sion profiling of triple-positive (MIXL1+/CD13+/ROR2+)
and triple-negative (MIXL1/CD13/ROR2) popula-
tions. Gene Ontology (GO) analysis revealed that the tran-
scripts enriched in the MIXL1+/CD13+/ROR2+ population
correlated with the processes of heart development (p =
6.79 3 1010), germ layer formation (p = 1.78 3 106),
gastrulation (p = 2.77 3 106), mesoderm development
(p = 5.52 3 106), and heart morphogenesis (p = 2.18 3
105) (Figures 1F and 1G).
We next sought to determine whether CD13 and ROR2
are expressed onMIXL1+ endoderm-derived cells. Flow cy-
tometric analysis of MIXL1GFP/w cells differentiated under
endodermal conditions (D’Amour et al., 2005) revealed no
substantial expression of CD13 or ROR2 on MIXL1-eGFP+
endodermcells (Figure 2A). This observationwas confirmed
by qPCR, demonstrating a 26- and a 2-fold decrease in the
expression of CD13 and ROR2, respectively, relative to
mesodermal MIXL1-eGFP+ cells (Figure 2B). Furthermore,
throughout differentiation 13R2+ cells expressed low levels
of endodermal markers, including SOX17, SOX7, FOXA2,
and HFN4A, relative to the CD13/ROR2 fraction (Fig-
ure 2C). To confirm the restriction of CD13 and ROR2
expression to mesoderm-derived cells, we tested for the
presence of the definitive endoderm cell-surface marker,
CXCR4 (McGrath et al., 1999; Yusuf et al., 2005). Flow cyto-
metric analysis ofmesoderm cells derived fromunmodified
H9 hESCs revealed that expression of CXCR4 and CD13/
ROR2 is mutually exclusive (Figure 2D). This differential
expression pattern was further confirmed by immunofluo-
rescence staining (Figures 3A and S2C). 13R2+ cells also
downregulated pluripotency markers, and expressed the
cardiac mesoderm markers MESP1 and MIXL1 (88% ±
2.3% SEM, n = 3) (Figures 1E, 1F, 2C, 3A, S2D, and S2E).
Together, these results indicate that CD13 and ROR2 can
be used to preferentially select for mesoderm from a mixed
population of differentiating hESCs.
In accordance with previous reports that an epithelial-to-
mesenchymal transition (EMT) occurs at an early stage of
mesoderm commitment, we analyzed the expression of
EpCAM/CD326 and NCAM/CD56 in 13R2+ fractions (Ev-
seenko et al., 2010). We observed that approximately 90%
of sorted 13R2+ cells expressed CD56 and downregulated
CD326 after 2 days of reculture, suggestive of an EMTrs
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Figure 1. CD13 and ROR2 Mark the Mesoderm
(A) Microarray analysis comparing the transcriptomes of MIXL1eGFP fractions reveals upregulation of CD13 (overall rank 1,230) and ROR2
(overall rank 564) as two surface markers in the mesodermal fraction.
(B) Day-3 flow cytometry analysis detailing CD13 and ROR2 expression in H3-MIXL1eGFP, hES2, and iPS cell lines.
(C) Flow cytometry analysis time course detailing expression of CD13 and ROR2 at days 0, 3, 7, and 10 of an efficient monolayer differ-
entiation. See also Figures S2A and S2B.
(D) Day-3 flow cytometry analysis showing CD13 and ROR2 expression in MIXL1+ and MIXL1 fractions.
(E) Day-3 qPCR analysis of CD13+/ROR2+ and CD13+/ROR2 cells in comparison with hESCs (n = 3; ±SEM).
(F) Single-gene qPCR analysis of the Mixl1eGFP+/CD13+/ROR2+ population showing expression levels of mesoderm-associated genes and
pluripotent genes (n = 1).
(G) Gene ontology analysis of Mixl1eGFP+/CD13+/ROR2+ detailing association with heart formation and mesoderm lineage development.
n represents the number of individual experiments in all instances.process and mesoderm specification (Figure 3B). Compara-
tively, the CD13/ROR2 (13R2) fraction was largely
CD56/CD326+ (87%), consistent with an epithelial
phenotype (Figures 3B and S2F). A proportion of the
day-3 CD13+ and 13R2+ fraction also expressed PDGFRa
(45.7% ± 2.1%, n = 3) and C-KIT (1.3% ± 0.8%, n = 3),
respectively (Figures S3A and S3B). Furthermore, 18.8% ±
6.4% (n = 3) of the ROR2+ fraction expressed KDR (Fig-
ure S3C). Nonetheless, a largemajority of day-3 13R2+ cells
were negative for SSEA1 (Figure S3E). Surface markers asso-
ciated with later stages of cardiac differentiation were also
absent from the 13R2+ population, including VCAM1,StemSIRPA, and CD34 (Figures S3F and S3G). Collectively, these
data suggest that CD13 and ROR2 mark a distinct, transi-
tory state of EMT committed cells and can be used to pro-
spectively enrich for pre-cardiac mesoderm, depleting
both endodermal and residual pluripotent cells.
CD13+/ROR2+ Cells Give Rise to Cardiomyocytes,
Smooth Muscle, and Endothelium In Vitro
Next, we sought to determine the efficiency at which
purified 13R2+ cells differentiate toward definitive cardio-
vascular lineages. To assist downstream characterization,
we generated a double reporter hESC line in which eGFPCell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authors 97
Figure 2. CD13 and ROR2 Preferentially
Select Mesoderm and Deplete Endoderm
(A) Day-3 flow cytometry analysis showing
expression of CD13, ROR2, and MIXL1-eGFP
in mesoderm and endoderm differentia-
tions.
(B) Day-3 qPCR analysis detailing expres-
sion of CD13 and ROR2 in hESCs, MIXL1+
(MG+), and MIXL1 (MG-) cells from endo-
derm (E) and mesoderm (M) differentiations
(n = 3; ±SEM).
(C) qPCR analysis detailing endodermal gene
expression in CD13/ROR2 fractions sorted at
days 3, 6, and 9 of differentiation.
(D) Day-3 flow cytometry analysis of un-
modified H9 mesoderm differentiation
showing co-expression of ROR2/CD13, but
not ROR2/CXCR4 or CD13/CXCR4.
n represents the number of individual ex-
periments in all instances.is expressed upon activation of endogenous NKX2-5 (El-
liott et al., 2011) and mCherry expression is controlled by
the aMHC promoter (Kita-Matsuo et al., 2009). This dual-
color hESC line facilitates identification and quantification
of cardiac progenitors and cardiomyocytes based upon
expression of NKX2-5 and aMHC, respectively. Sorted
13R2 cells did not survive in our monolayer differentia-
tion protocols for the extended time period required for
analysis, so unsorted cells served as a control.
Isolated 13R2+ cells were recultured under conditions
promoting cardiomyocyte differentiation to characterize
their developmental potential. Seven days post sort,
86% ± 3.2% (n = 3) of 13R2+ cells proceeded to express
NKX2-5eGFP, compared with 22% ± 4.9% (n = 3) in the un-
sorted population (Figure 4A). Furthermore, 63% ± 4.1%
(n = 3) of 13R2+ cells differentiated to express mCherry
in addition to eGFP (indicating progression to cardiomyo-
cytes), whereas only 16% ± 4.0% (n = 3) of the unsorted
population was observed to be eGFP+/mCherry+ (Figures
4A and S4A). Although differentiation efficiency varied98 Stem Cell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authosignificantly in unsorted cells, we observed a persistently
high rate of cardiomyocyte generation when selecting for
CD13/ROR2. Gene expression analysis supported these
findings, and demonstrated that differentiating 13R2+ cells
temporally expressed high levels of cardiac mesoderm
genes followed by cardiovascular progenitor and definitive
cardiomyocyte genes (Figures 4B and S4B). This was illus-
trated by elevated expression levels of HAND1 and MIXL1
at day 4, followed by ISL-1, MEF2C, TBX5, and NKX2-5
by days 7–10, and cTnT, MYL2, IRX4, and NPPA at later
stages (Figures 4B and S4B). In addition, when we analyzed
expression of eGFP and mCherry on days 7 and 14 as
markers for NKX2-5 and aMHC, respectively, we noted
higher expression levels in 13R2+ cells when compared
with either day-3 sorted single positive CD13 or ROR2,
day-4 sorted SSEA1+, and day-5 sorted PDGFR+/KDR+
populations (Figures S4C–S4H). Furthermore, when main-
tained in a monolayer culture, 13R2+ cells displayed car-
diac troponin T (cTnT)-positive sarcomeric structures, and
formed contractile 3D layers (Figures 4C and Movie S1).rs
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Figure 3. CD13 and ROR2 Mark a Distinct,
Transitory Pre-cardiac Mesoderm Popu-
lation
(A) Day-4 ICC analysis of sorted 13R2+ and
13R2 cells from hESC mesoderm differen-
tiations, showing expression of MIXL1,
MESP1, CXCR4, and GATA4. Scale bars,
25 mm. See also Figures S2C and S2D.
(B) Day-5 flow cytometric analysis of un-
sorted and sorted 13R2+ and 13R2 cells for
expression of CD326 and CD56. See also
Figure S2F.Together, these results suggest that 13R2+ cells give rise to a
highly enriched population of cardiomyocytes.
We next sought to determine whether 13R2+ cells can
give rise to other cardiovascular lineages. Under cardio-
myocyte culture conditions, a proportion of the day-3
sorted 13R2+ fraction progressed toward an aSMA+ pheno-
type (Figure 4C). Furthermore, the expression level of
smooth muscle transcripts, ACTA2 (aSMA) and CNN1,
were significantly higher in 13R2+ cells at various time
points during days 7–14 of differentiation (p < 0.05) (Fig-
ure 4D). To further investigate the lineage potential of the
13R2+ fraction, we cultured day-3 sorted 13R2+ cells under
conditions to promote smooth muscle differentiation
(transforming growth factor b 2 ng/ml, platelet-derived
growth factor b 10 ng/ml) (Cheung et al., 2014). After
11 days in culture, 13R2+ cells expressed high levels of
ACTA2 (aSMA) and CNN1 transcripts, and low levels of
VE-cadherin, consistent with a smooth muscle phenotype
(Figure 4E). Enrichment for smooth muscle cells in the
differentiated 13R2+ population was confirmed by pro-
tein-level expression of aSMA and CNN1, as determined
by immunocytochemistry (ICC) (Figure S4I).StemA fraction of 13R2+ cells also differentiated toward a VE-
cadherin+ phenotype in standard cardiomyocyte differen-
tiations (Figure 4C). To further characterize endothelial
differentiation, we cultured day-3 sorted 13R2+ cells under
endothelial conditions (50 ng/ml vascular endothelial
growth factor, 20 ng/ml stem cell factor, 10 ng/ml basic
fibroblast growth factor). After 11 days of culture under
these conditions, 13R2+ cells expressed high levels of the
endothelial markers VE-cadherin, TAL1, TEK, KDR, and
vWF (Figure 4E). Furthermore, after 14 days flow cytomet-
ric analysis revealed that a subset of sorted 13R2+ cells pro-
ceeded to co-express CD31/CD34 and CD31/KDR (32%
and 37%, respectively), consistent with an endothelial
phenotype (Figures 4F and S4J). Taken together, these re-
sults suggest that 13R2+ cells on day 3 of differentiation
represent cardiovascular mesoderm capable of giving rise
to cardiomyocytes, smooth muscle, and endothelial cells.
Temporal Gene Expression Profiling of CD13+/ROR2+
Cells and Their Progeny
To determine the gene expression profile at different stages
of cardiac differentiation from hESCs, we performedCell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authors 99
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Figure 4. CD13+/ROR2+ Cells Give Rise to Enriched Cardiomyocyte Populations and Differentiate toward Endothelial and Smooth
Muscle Cells
(A) Day-10 flow cytometric analysis of day-3 sorted 13R2+ and unsorted cells showing expression of NKX2-5eGFP and aMHC-mCherry
(n = 3; ±SEM). See also Figure S4A.
(B) qPCR time course detailing the expression of cardiac mesoderm and definitive cardiomyocyte genes over 14 days of differentiation
relative to GAPDH (n = 3; ±SEM). See also Figure S4B.
(C) Immunofluorescence analysis of 13R2+ cells after 12 days in culture for markers of cardiomyocytes (cTnT), endothelial (VE-cadherin),
and smooth muscle cells (aSMA). Scale bars, 10 mm.
(D) qPCR analysis of smooth muscle genes over 14 days of differentiation in unsorted and sorted 13R2+ cell fractions, relative to GAPDH
(n = 3; ±SEM).
(E) Day-14 qPCR analysis of endothelial and smooth muscle cultured 13R2+ cells relative to GAPDH (n = 3; ±SEM) (see also Figures S4I
and S4J).
(F) Day-14 flow cytometry analysis of endothelial cultured 13R2+ cells showing co-expression of CD31/CD34 and CD31/KDR, respectively.
n represents individual experiments in all instances.transcriptome (RNA-seq) analysis on undifferentiated
hESCs, 13R2+ and 13R2 populations from day 3, 13R2+/
NKX2-5+, and 13R2+/NKX2-5 from day 7, and 13R2+/
NKX2-5+/aMHC+ and 13R2+/NKX2-5+/aMHC from day
14 (Figure S5). These data supported previous findings
showing an enrichment of pre-cardiac mesodermal genes
and concomitant downregulation of pluripotency genes
in the 13R2+ population on day 3 (Figure 5A). Day-7
13R2+/NKX2-5+ cells expressed cardiac transcription fac-
tors such asMEF2-C,NKX2-5,TBX20, andTBX5, suggestive100 Stem Cell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authof commitment to a cardiac progenitor cell type (Figure 5A).
Day-7 13R2+/NKX2-5+ cells were also enriched for cardio-
myocyte markers TNNT2, KCNIP2, KCNH7, andMYL4 (Fig-
ure 5A). The day-14 13R2+/NKX2-5+/aMHC+ fraction
maintained expression of these cardiomyocyte markers, in
addition to upregulating other cardiomyocyte genes such
as NPPA, NPPB, MYH7, and MYL7, suggestive of a progres-
sion toward a more differentiated cardiomyocyte pheno-
type (Figure 5A). In addition, both day-14 13R2+/NKX2-
5+/aMHC+ and 13R2+/NKX2-5+/aMHC populationsors
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Figure 5. CD13+/ROR2+ Downstream Gene Ontology and In Vivo Kidney Capsule Differentiation
(A) RNA-seq time-course analysis of hESCs, day-3 13R2+ and 13R2 cells, day-7 13R2+-derived NKX2-5+ and NKX2-5 cells, day-14
13R2+/NKX2-5+-derived aMHC+ and aMHC cells (see also Figure S5). Genes are grouped into seven categories, including pluripotency,
mesoderm, cardiac progenitor, cardiomyocyte, smooth muscle (SM), fibroblast (FB), and endothelium (EC) (n = 1).
(B) GO analysis showing GO terms associated with upregulated gene expression in day-7 13R2+-derived NKX2-5+ and day-14 13R2+/NKX2-
5+-derived aMHC+ populations.
(C and D) Gross anatomical (C) and immunohistochemistry (IHC) images (D) of kidney capsule sections 6 weeks after injection with 13R2+
cells. IHC images show expression of TBX5 (red), CNN1 (red), and cTnT (red), respectively. Nuclei are stained with DAPI (blue). Scale bars
represent 5 mm (C) and 25 mm (D) (n = 3).
n represents the number of individual experiments in all instances.were enriched for smooth muscle genes, such as MYH11,
CNN1, and ACTA1, suggesting that these populations may
also contain vascular smooth muscle cells (Figure 5A).
GO analysis of the upregulated transcripts in day-7
13R2+/NKX2-5+ and day-14 13R2+/NKX2-5+/aMHC+
fractions generated a list of 100 GO terms with p <
0.0005. These included voltage-gated calcium channels
(p = 4.9 3 1026), heart morphogenesis (p = 1.56 3
1012), muscle contraction (p = 2.15 3 109), myofibril as-
sembly (p = 2.46 3 108) and calcium ion transport
(p = 1.04 3 106), further confirming the progression of
13R2+ progenitors toward cardiac cell types, and in partic-Stem Cular cardiomyocytes (Figure 5B). The transcriptional
profile of CD13/ROR2 fractions and their progeny maps
out the developmental hierarchy of a putative pre-cardiac
mesodermal cell population that differentiates to cardiac
progenitors with subsequent specification to mature
cardiomyocytes.
Transplantation of CD13/ROR2 Cells in a Murine
Model
To determine whether 13R2+ cells retain an in vivo latent
potential to differentiate to a cardiovascular lineage, we
transplanted these cells into the mouse kidney capsuleell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authors 101
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Figure 6. In Vivo Differentiation and Engraftment of CD13+/ROR2+ Cells in the Mouse Heart
(A) IHC analysis of explanted mouse hearts 6 weeks after injection with 13R2+ cells showing staining for humanmitochondria (red). Nuclei
are stained with DAPI (blue). Scale bars, 100 mm (n = 6). See also Figure S6.
(B) IHC analysis of explanted mouse hearts 6 weeks after injection with 13R2 cells showing staining for human mitochondria (red).
Nuclei are stained with DAPI (blue). Scale bars, 200 mm (see also Figure S6A). IHC H&E staining of 13R2 cell-derived teratomas is also
shown (see also Figure S6A). Scale bars, 200 mm (n = 6). See also Figure S6.
(C) IHC analysis of explanted mouse hearts 6 weeks after injection with endothelially directed 13R2+ cells showing expression of human
mitochondria (red), vWF (green), and CD31 (green), respectively. Nuclei are stained with DAPI (blue). Scale bars, 25 mm (n = 6).
(D) IHC analysis of explanted mouse hearts 6 weeks after injection with smooth muscle-directed 13R2+ cells showing expression of human
mitochondria (red), CNN1 (green), and MYH11 (green), respectively. Nuclei are stained with DAPI (blue). Scale bars, 25 mm (n = 6).
n represents the number of individual experiments in all instances.and heart. Day-3 13R2+ cells were isolated from a differen-
tiatingNKX2-5GFP/w hESC reporter line (Elliott et al., 2011),
recovered for 24 hr in culture, and approximately 5 3 105
cells were implanted under the kidney capsule of non-
obese diabetic/SCID mice with common g-chain knockout
(NSG) (Figure 5C). Six weeks later, 13R2+ grafts had eGFP+
patches demonstrating NKX2-5 expression. Transplanted
13R2+ progeny also contained cells expressing cardiac pro-
genitor (TBX5), smooth muscle (CNN1), and cardiomyo-
cyte (cTnT) proteins (Figure 5D). However, these grafts
were not contractile and did not form organized sarcomeric
structures. Furthermore, transplanted 13R2+ cells did not
express the endothelial markers CD31 and APJ. These
data indicate that the mouse kidney capsule may not pro-
vide a supportive environment for human myocardial or
endothelial differentiation.
Differentiation potential of day-3 13R2+ cells was also
tested in the mouse heart. Approximately 5 3 105 13R2+
(or 13R2) cells were sorted and recultured for 24 hr before102 Stem Cell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authtransplantation by direct injection into the left ventricle of
healthy NSG mouse hearts, or into the peri-infarct area
following occlusion of the left anterior coronary descend-
ing artery (n = 6 in each group). Control experiments
included equivalent volumes of conditionedmedia admin-
istered in similar locations of healthy and injured mouse
hearts (n = 6). Engraftment was examined 8 weeks after
transplantation by screening for human mitochondria
staining in sectioned hearts (Figure 6). We detected very
limited survival and engraftment of transplanted 13R2+
cells in the healthy NSG mouse hearts, and no substantial
human cells in injured hearts. Engrafted 13R2+ cells did
not express markers of definitive cardiac cell lineages, and
no teratomas were observed (Figure 6A). Conversely, trans-
planted 13R2 cells formed teratomas, with mesoderm,
endoderm, and ectoderm derivatives, in healthy (two of
six) and injured (one of six) mouse hearts, suggesting the
presence of residual undifferentiated hESCs (Figures 6B
and S6A). Cardiac function, assessed by echocardiographyors
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Figure 7. Transplanted CD13+/ROR2+ Cells Can Engraft and Differentiate in Pig Hearts
(A–H) Myocardial sections from porcine hearts 40 days after transplantation of 13R2+ cells show clusters of hESC-derived cardiovascular
cells (see also Figure S7). IHC stains depict the expression human mitochondria (red), as well as cTnC (A), cTnT (B), CD31 (C), vWF (D),
CNN1 (E), MYH11 (F), DDR2 (G), and Col 1 (H) (green), respectively. Nuclei are stained with DAPI (blue). Scale bars, 50 mm (n = 3). See also
Figures S7B–S7E.
(I and J) A cluster of hESC-derived cardiomyocytes marked by human mitochondria (red) and cTnT (red) that demonstrates diffuse
expression of Connexin 43 (green, marked by white arrowheads) between the transplanted cells. Scale bars, 20 mm (n = 3).
n represents the number of individual experiments in all instances.at baseline and 8 weeks after intervention, revealed no
changes in the ejection fraction or fractional shortening
between groups (sham, conditioned media, 13R2+, or
13R2 transplants; n = 6 in each group) (Figure S6B).
While several studies have examined hESC-derived cardi-
omyocytes in murine hearts, less is known of the capacity
of human smooth muscle and endothelial cells to improve
heart function, possibly by neovascularization of the
damaged tissue (Li et al., 2009; Xiong et al., 2012). We
transplanted a total of approximately 53 105 smoothmus-
cle and/or endothelial cells (derived from pre-sorted 13R2+
cells after 17 days in culture) into healthy and peri-
infarcted areas of NSGmouse hearts (n = 12 in each group).
Control experiments included equivalent volumes of
conditioned media administered in similar locations of
healthy and injured mouse hearts (n = 6). We observed
rare hESC-derived vascular smooth muscle or endothelial
cell engraftment in the injured mouse hearts. In healthy
mouse hearts, very few 13R2+ cells successfully engrafted
and expressed the endothelial markers vWF andCD31 (Fig-
ure 6C), or smoothmusclemarkers CNN1 andMHY11 (Fig-
ure 6D), respectively. No difference in cardiac function,
based on echocardiographic measurements, was observed
between treatments, i.e. sham, conditioned media, or cell
transplantation (Figure S6C). Collectively these resultsStem Cindicate that the mouse heart, particularly after MI,
may not provide a supportive niche for the engraftment
of hESC-derived populations enriched for cardiovascu-
lar cells. Nevertheless, terminally differentiated 13R2+-
derived smooth muscle and endothelium can engraft into
the uninjured mouse heart, albeit at a very low frequency.
Taken together, thesemouse studies highlight the necessity
to establish a clinically relevant large animal model to
investigate transplantation of hESC-derived CPCs.
CD13+/ROR2+ Cells Engraft and Differentiate toward
Cardiomyocytes, Endothelium, Smooth Muscle, and
Fibroblasts in Pig Hearts
To provide a more relevant model to test the 13R2+ cell
type for cardiac regeneration, we used a porcine model.
Approximately 40 3 106 13R2+ cells were transplanted by
direct injection into the left ventricle of healthy Yorkshire
pig hearts, which remained on immunosuppressive ther-
apy for the duration of the study (Figure S7A). The animals
were euthanized after 40 days, and histological analyses of
the explanted hearts showed numerous clusters of cells
varying in size (5 to >1,000) staining positive for human
mitochondria (Figures S7B–S7E; Figure 7A). Transplanted
13R2+ cells also expressed markers of cardiomyocytes
(cTnC, cTnT) (Figures 7A and 7B), vascular endotheliumell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authors 103
(CD31, vWF) (Figures 7C and 7D), smooth muscle cells
(CNN1, MYH11), (Figures 7E and 7F), and fibroblasts
(DDR2, Col1) (Figures 7G and 7H). In addition, we
observed expression of CX43 between transplanted
13R2+-derived cardiomyocytes (Figures 7I and 7J). We did
not detect the presence of CX43 between the graft and
host myocardium. hESC-derived cardiomyocytes had
highly organized myofibrils aligned with the host myocar-
dium, suggestive of a maturing cardiomyocyte phenotype
(Figures 7A, 7B, and 7I). Furthermore, 13R2+-derived endo-
thelial and vascular smooth muscle cells contributed to
vessel formation (Figures 7C–7F). No teratomas were
observed in any of the animals transplanted with 13R2+
cells. Furthermore, no CD45+ cells were found near the en-
grafted hESC-derived cells, suggesting absence of immune
cell infiltration to the graft site at the time of histological
examination. However, consistent with other studies, we
noted that the majority of the transplanted cells (>90%)
were not retained in the recipient hearts (Ardehali et al.,
2013; Blin et al., 2010; Chong et al., 2014; Mani
et al., 2008; Tallheden et al., 2006; Thu et al., 2012; Ye
et al., 2014). It should also be noted that we observed a
small fraction of the 13R2+ transplanted cells within the
heart that did not express any cardiovascular markers
(approximately 10%–20%) and remained isolated from
the surrounding host tissue (Figure S7C). Nonetheless,
these data suggest that hESC-derived 13R2+ cells are
capable of engrafting in the pig myocardium and differen-
tiating toward cardiomyocytes, vascular endothelial cells,
smooth muscle cells, and fibroblasts.DISCUSSION
The identification of CD13 and ROR2 as early cardiogenic
markers contributes to the establishment of a detailed car-
diac lineage fate map and may subsequently aid develop-
mental studies. Other cell-surface markers for isolation of
mesoderm and cardiac progenitors have previously been
reported (Ardehali et al., 2013; Blin et al., 2010; Drukker
et al., 2012; Kattman et al., 2011; Skelton et al., 2014;
Yang et al., 2008). Two such mesodermal markers for the
isolation of cardiovascular progenitors from hESCs are
PDGFRa and KDR (Ardehali et al., 2013; Kattman et al.,
2011). However, not all cells selected by these markers are
committed to the cardiovascular fate (Kattman et al.,
2011). Furthermore, it was recently reported that MESP1+
cardiac mesoderm populations are enriched for PDGFRa+
and CD13+/ROR2+, but not PDGRRa+/KDR+ progenitors
(Den Hartogh et al., 2015). This suggests that CD13 and
ROR2 may mark a subset of cardiac mesoderm separate to
that of the PDGFRa+/KDR+ fraction. Our results support
these findings, as at day 3 of differentiation just under104 Stem Cell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authhalf of CD13+ cells co-expressed PDGFRa, and a small per-
centage (18.8% ± 6.4%, n = 3) of ROR2+ cells were KDR pos-
itive. In addition, very few 13R2+ cells expressed SSEA1
(0.3% ± 0.25%, n = 3) on day 3, supporting the notion
that multiple progenitor subsets may exist at early stages
of hESC cardiac differentiation. However, this may be due
to the slight differences that exist between the expression
patterns of these markers, with CD13/ROR2 being most
highly upregulated at day 3, SSEA1 at day 4 (Blin et al.,
2010), and PDGFRa/KDR at day 5 (Kattman et al., 2011)
of cardiac differentiation. Further investigation is required
to determine the temporal expression profile of these
markers during cardiovascular differentiation.
Our results indicate that CD13 and ROR2 can be used to
separate mesoderm from endoderm in a MIXL1+ back-
ground. It was noted that the day-4 CD13/ROR2 popu-
lation largely consists of a MIXL1+/MESP1/GATA4+/
CXCR4+ cell type, consistent with an endodermal pheno-
type. Throughout differentiation, the CD13/ROR2 frac-
tion also expressed high levels of endoderm markers, such
as SOX17, SOX7, FOXA2, and HFN4A. Thus, at later stages
of differentiationCD13 andROR2mayhave utility as nega-
tive selection markers for endoderm. However, at day 3 of
differentiation the CD13/ROR2 population also con-
tained residual pluripotent cells that led to teratoma forma-
tion in the mouse hearts.
Flow cytometry data revealed a high degree of overlap be-
tween the surface expression of CD13 and ROR2. Few
studies have detailed CD13 and ROR2 expression in the
context of early cardiac development. Thus, it remains
difficult to determine whether CD13/ROR2 co-expression
in pre-cardiac mesoderm is coincidental, or due to a
requirement for both in a shared (or interacting) develop-
mental pathway(s). CD13 and ROR2 have biologically
diverse roles, with CD13 commonly being associated
with hematopoiesis and cancer (Dalal et al., 2014; Estey,
2013; Gorczyca et al., 2011; Zhang et al., 2011), and
ROR2 regulating cellular processes via non-canonical Wnt
signaling, withmutations in ROR2 leading to Robinow syn-
drome (Afzal et al., 2000; Minami et al., 2010; Oishi et al.,
2003). While this study shows that CD13 and ROR2 are ex-
pressed on a transitory population of early pre-cardiac
mesodermal cells, their precise role in cardiac specification,
if any, remains to be determined.
The application of surface markers to isolate pure tissue-
specific progenitors offers several advantages for cell
transplantation. First, it allows for isolation of a highly en-
riched, lineage-committed progenitor population. Second,
it eliminates residual undifferentiated cells with the poten-
tial to form teratomas upon transplantation. Finally, it
allows for a detailed investigation to delineate the develop-
mental potential of progenitors after transplantation
into the host. Successful transplantation of hESC-derivedors
cardiomyocytes has been reported in rodents (Ardehali
et al., 2013; Ban et al., 2013; Hattori et al., 2010), guinea
pigs (Shiba et al., 2012), and non-human primate models
of myocardial ischemia (Blin et al., 2010; Chong et al.,
2014). In contrast to some previous studies using more
committed cell types, we did not identify any hESC-derived
cardiomyocytes after transplantation of 13R2+ cardiac pro-
genitors in the healthy or injured hearts of SCIDmice. This
may be due to the poor engraftment of the less mature,
mesodermal 13R2+ cell type. After transplanting hESC-
derived endothelial and smooth muscle cells into the
mouse heart, we observed rare engraftment, representing
less than 0.1% of total transplanted cells. Consistent with
previous reports, no long-term cardiac functional improve-
ment was observed in mice treated with hESC-derived cells
(van Laake et al., 2007, 2008, 2009). Other groups have
yielded more positive results using species-matched
induced PSC (iPSC)-derived cardiac progenitors (Lalit
et al., 2014; Mauritz et al., 2011; Pasha et al., 2011). For
instance, Mauritz et al. (2011) observed that murine iPSC-
derived Flk-1+ progenitors were capable of engrafting and
functionally improving injured mouse heart. Thus, the
observed lack of engraftment and differentiation by
hESC-CPCsmay be partially due to the inherent differences
between mice and humans, reaffirming the importance of
appropriate animalmodels for pre-clinical cardiac cell ther-
apy development.
The pig hasmany advantages overmousemodels for pre-
clinical studies involving hESC-CPC transplantation,
namely its similar heart size and physiology to human. In
addition, pig cardiomyocytes have been shown to exhibit
similar contraction rates and analogous action potential
duration to humans (Stankovicova et al., 2000). We sought
to determine whether CD13+/ROR2+ pre-cardiac meso-
dermal cells could engraft into the porcine myocardium
and further differentiate into cardiovascular lineages. We
chose to deliver 13R2+ cells into uninjured pig hearts to
eliminate the many variables associated with the injury
process. Extensive ICC analysis was performed, as in this
context the NKX2-5eGFP and aMHC-mCherry fluorescence
could not be reliably distinguished from the highly auto-
fluorescent background. Our results indicated that many
transplanted 13R2+ cells survived, engrafted, and differen-
tiated toward definitive cardiovascular cell types in the pig
heart after approximately 6 weeks. We observed small
vessels that incorporated 13R2+-derived endothelial and
vascular smooth muscle cells. In addition, we identified
numerous areas within the pig’s heart containing 13R2+-
derived cardiomyocyte clusters ranging from 5 to >1,000
cells. Interestingly, many of these cells had organized
sarcomere and formed Connexin-43 junctions between
adjacent grafted cells. Whether 13R2+ cells are able to
structurally and functionally integrate into the hostStem Cmyocardium and offer a therapeutic benefit to injured pig
heart warrants further investigation. Such studies will be
particularly important, given there is a negligible difference
between the engraftment potential of hESC-derived cardio-
myocytes and cardiac mesoderm (Chong et al., 2014). Ulti-
mately, it is possible that combinations of different cell
types (i.e. cardiomyocytes and cardiac progenitors) may
improve graft survival and functional outcomes (Xiong
et al., 2012; Ye et al., 2014).
In conclusion, this study demonstrates the utility of the
cell-surface proteins CD13 and ROR2, which mark a popu-
lation highly enriched for pre-cardiac mesoderm. Further-
more, we have shown that CD13+/ROR2+ cells are able to
survive, engraft, and differentiate toward definitive cardiac
cell types in pig, but not mouse hearts, highlighting the
importance of clinically relevant animal models. Ulti-
mately, the identification of CD13 and ROR2 as markers
of early cardiac mesoderm may set the platform for future
clinical trials for delivery of an enriched population of pro-
genitors committed to the cardiovascular lineage without
the risk of teratoma formation.EXPERIMENTAL PROCEDURES
Maintenance of hESCs
Pluripotent MIXL1-eGFP, NKX2-5eGFP, and NKX2-5eGFP/aMHC-
mCherry hESC lines weremaintained as described previously (Davis
et al., 2008; Pick et al., 2007).Differentiation of hESCs
Cardiomyocyte monolayer differentiations were performed as pre-
viously described (Skelton et al., 2014).Large Animal Cell Injection and Maintenance
Animal housing, maintenance, and experimentation were
approved by and in accordance with guidelines set by the Institu-
tional Animal Care and Use Committee of the University of
California and the NIH Guide for the Care and Use of Laboratory
Animals. A total of three 6- to 7-week-old Yorkshire pigs weighing
approximately 40–45 kg underwent thoracotomy and transplanta-
tion of hESC-CPCs under direct visualization. Two injection sites
were selected on the left ventricular free wall and marked with a
suture. A suspension of 4 3 107 cells in approximately 300 ml of
conditioned media was injected in each site using a 27-gauge nee-
dle. Pigs were immunosuppressed with cyclosporine (serum level
maintained at 100–120 ng/ml), and treated with ketoconazole
(20 mg/kg) and trimethoprim/sulfamethoxazole (40 mg/kg) daily,
which began 3 days prior to cell transplantation until euthanasia.
After 40 days the pigs were euthanized, and hearts were harvested
and sectioned for histological analysis.
Statistical Analysis
Statistical testing was performed with Microsoft Excel version
12.2.8 and GraphPad Prism. Results are presented as mean ± SEMell Reports j Vol. 6 j 95–108 j January 12, 2016 j ª2016 The Authors 105
and were compared using a two-tailed Student t test or two-way
ANOVA (significance was assigned for p < 0.05). n represents the
number of individual experiments in all instances.
Please refer to Supplemental Materials and Methods for full
details of Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Materials and
Methods, seven figures, two tables, and one movie and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2015.11.006.
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